TGFB3 protein, human clinical trials
Also written Avotermin, Juvista and RN1001.
How each study uses TGFB3 protein, human is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
18 studies that test it; most in 2006 (4)
| Year | Studies |
|---|---|
| 2001 | 2 |
| 2002 | 3 |
| 2003 | 3 |
| 2004 | 2 |
| 2006 | 4 |
| 2008 | 2 |
| 2009 | 2 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 18 · Other 0
Studies
Open first, then newest update. How each study uses TGFB3 protein, human is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 18
- Juvista in Scar Revision Surgery of Disfiguring ScarsCompletedPhase 3RenovoNCT00742443Written as Juvista (avotermin)How we know
- A Trial to Compare the Efficacy of Two Formulations of Avotermin Against PlaceboCompletedPhase 1RenovoNCT01029158Written as Juvista (Avotermin)How we know
- Juvista (Avotermin) in Scars Following Varicose Vein RemovalCompletedPhase 2RenovoNCT00430326Written as AvoterminHow we know
- Safety of Juvista When Administered Following Excision of Ear Lobe KeloidsCompletedPhase 1/2RenovoNCT00710333Written as AvoterminHow we know
- Juvista in the Non-surgical Improvement of Existing ScarsWithdrawnNot applicableRenovoNCT00821457Written as JuvistaHow we know
- Safety and Efficacy Study of Avotermin (Juvista) in Female SubjectsCompletedPhase 1/2RenovoNCT00984581Written as AvoterminHow we know
- Investigation of the Accelerated Healing and Anti-scarring Potential of Avotermin (Juvista) in Split Skin Graft Donor SitesCompletedPhase 2RenovoNCT00984503Written as AvoterminHow we know
- Investigation of the Safety, Dosing Frequency and Anti-Scarring Potential of Two Concentrations of Intradermal Avotermin (Juvista)CompletedPhase 1/2RenovoNCT00978367Written as AvoterminHow we know
- Safety Study of Repeated, Escalating Doses of Intradermal Avotermin (Juvista)CompletedPhase 1RenovoNCT00978302Written as AvoterminHow we know
- Genomic Changes Associated With the Use of Intradermal Avotermin (Juvista) in Small Wounds in Healthy Male SubjectsCompletedPhase 1/2RenovoNCT00977951Written as Intradermal avoterminHow we know
- Safety and Efficacy of RN1001(Avotermin) in Healthy Male SubjectsCompletedPhase 1/2RenovoNCT00847925Written as Avotermin (RN1001)How we know
- Efficacy and Safety of Intradermal RN1001 (Avotermin) in Elderly Subjects.CompletedPhase 1/2RenovoNCT00847795Written as AvoterminHow we know
- Juvista (Avotermin) in Breast Reduction Surgery ScarsTerminatedPhase 2RenovoNCT00432328Written as AvoterminHow we know
- RN1001(Avotermin) in Scar Improvement Following Breast AugmentationCompletedPhase 2RenovoNCT00436449Written as AvoterminHow we know
- A Trial to Investigate Scar Improvement Efficacy of RN1001 (Avotermin) After Head and Neck Naevi ExcisionStatus unknownPhase 2RenovoNCT00656227Written as AvoterminHow we know
- Improvement in Scar Appearance Following Injection of Avotermin (Juvista) Into Skin Incisions Made in Healthy Men and WomenCompletedPhase 2RenovoNCT00629811Written as Avotermin (Juvista)How we know
- Scar-Improvement Efficacy and Safety of a Single Intradermal Injection of Avotermin (Juvista) Administered Following Full-Thickness Skin IncisionsCompletedPhase 2RenovoNCT00627536Written as AvoterminHow we know
- Anti-Scarring Efficacy and Safety of Intradermal Juvista (Avotermin) in Healthy MalesCompletedPhase 2RenovoNCT00594581Written as Juvista (avotermin) plus placebo, standard-care (within-subject controls)How we know
Codes
What other systems call TGFB3 protein, human · ClinicalTrials.gg INT004887
- MeSH (NLM) C509044TGFB3 protein, humanOne source NLM
- UNII (FDA) 2Q1GS25JWNAVOTERMINConfirmed FDA, NLM
- RxNorm 1427086One source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C509044 | TGFB3 protein, human | One source NLM |
| UNII (FDA) | 2Q1GS25JWN | AVOTERMIN | Confirmed FDA, NLM |
| RxNorm | 1427086 | — | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.